Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Viasat — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Viasat trades at $61.37 (market cap $9.21B). The key difference: Kymera Therapeutics Inc. Common Stock and Viasat are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Viasat for 8 Days on average.
| KYMR | VSAT | |
|---|---|---|
Market Cap | $8.87B | $9.21B |
Volume | 779,107 | 1,494,317 |
Sector | Health | Technology |
52-Week High | $127.31 | $89.81 |
52-Week Low | $55.80 | $30.35 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $8.26B | $14.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VSAT trades at $66.9, down 1.12% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $574.96 million in 2025, though revenue grew to $4.52 billion. Recent positive developments include the ViaSat-3 F2 and F3 satellites entering service and a $1 billion joint venture with Space42 to create Equatys for direct-to-device connectivity, signaling growth potential in government and commercial markets.
The outlook is mixed; analyst consensus is a Buy with a $94.29 price target, but near-term profitability challenges and high debt levels pose risks. The stock's investment case hinges on execution of new contracts and satellite deployments driving future earnings growth beyond current losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
